Chow Man-Chie, Chambers Pinkie, Singleton Georgina, Patel Jignesh, Cooper Silvie, Mythen Charlotte, Bautista-González Elysse, Chisnall Georgia, Djellouli Nehla, Thwaites Benjamin, Wong Ian Ck, Vindrola-Padros Cecilia
Pharmacy Department, University College London Hospitals NHS Foundation Trust, UCLH-UCL Centre for Medicines Optimisation Research and Education, London, UK.
Department for Targeted Intervention, UCL/UCLH Surgical Outcomes Research Centre, Centre for Perioperative Medicine, University College London, London, UK.
J Oncol Pharm Pract. 2021 Jul;27(5):1073-1079. doi: 10.1177/10781552211015767. Epub 2021 May 13.
In response to the COVID-19 pandemic, changes to chemotherapy services were implemented as a means of managing imposed workload strains within health services and protecting patients from contracting COVID-19. Given the rapidly evolving nature of the pandemic many changes were rapidly adopted and were not substantiated by robust evidence. This study aimed to describe the changes adopted internationally to chemotherapy services, which may be used to guide future changes to treatment delivery.
A survey was developed to understand the impact of COVID-19 on the delivery of systemic anti-cancer therapies (SACT). It comprised 22 questions and examined the strategies implemented during the pandemic to prioritise and protect patients receiving SACT and the participants' professional opinion of the strategies employed. The survey was available in English, Spanish and French and was distributed via professional bodies.
129 responses were obtained from healthcare professionals working across 17 different countries. 45% of institutions had to implement treatment prioritisation strategies and all hospitals implemented changes in the delivery of treatment, including: reduction in treatments (69%), using less immunosuppressive agents (50%), allowing treatment breaks (14%) and switching to oral therapies (45%). Virtual clinic visits were perceived by participants as the most effective strategy to protect patients.
The pandemic has forced chemotherapy healthcare professionals to adopt new ways of working by reducing health interactions. Many areas of research are needed following this period, including understanding patients' perceptions of risks to treatment, utilisation of oral treatments and the impact of treatment breaks on cancer outcomes.
为应对新冠疫情,对化疗服务进行了调整,以应对医疗卫生服务中面临的工作量压力,并保护患者免受新冠病毒感染。鉴于疫情形势迅速演变,许多调整措施迅速出台,但缺乏有力证据支持。本研究旨在描述国际上对化疗服务所做的调整,这些调整可用于指导未来治疗方案的改变。
开展了一项调查,以了解新冠疫情对全身抗癌治疗(SACT)的影响。该调查包含22个问题,考察了疫情期间为优先保障和保护接受SACT治疗的患者所实施的策略,以及参与者对所采用策略的专业看法。该调查提供英文、西班牙文和法文版本,并通过专业机构进行分发。
从17个不同国家的医疗专业人员那里获得了129份回复。45%的机构不得不实施治疗优先排序策略,所有医院都对治疗方式进行了调整,包括:减少治疗(69%)、减少免疫抑制剂的使用(50%)、允许治疗中断(14%)以及改用口服疗法(45%)。参与者认为虚拟门诊是保护患者最有效的策略。
疫情迫使化疗医疗专业人员通过减少医疗接触来采用新的工作方式。在此期间之后,还需要开展许多领域的研究,包括了解患者对治疗风险的认知、口服治疗的使用情况以及治疗中断对癌症治疗结果的影响。